Ask HopeStage to review this study with me
Study ID: NCT05921929. We help you review the study, but cannot decide medical eligibility.
WithdrawnNCT05921929
Safety study of fluoroethylnormemantine in PTSD; Alzheimer Disease; Brain Diseases; Neuro-Degenerative Disease; depression; Treatment Resistant Depression
This study was withdrawn in Belgium. It is testing fluoroethylnormemantine for PTSD; Alzheimer Disease; Brain Diseases; Neuro-Degenerative Disease; depression; Treatment Resistant Depression.
Depression, PTSD, ...DrugFrom 18 Years to 45 Years
Key information made simple
What is this study testing?
This study is testing whether Fluoroethylnormemantine (FENM) may be useful for adults experiencing depression.
What would participation involve?
Participants may receive Fluoroethylnormemantine (FENM), complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in Belgium.
Who is it mainly for?
This study appears to be mainly for adults with depression.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record does not clearly describe the visit format, so the practical details are best checked directly in the source. Participation appears to involve study activities and follow-up chosen by the research team. The main fit and exclusions are best confirmed in the eligibility section of the official record. The phase details are not clearly stated here.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Withdrawn
- Estimated enrollment
- Not clearly listed
- Sponsor
- ReST Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- PHASE1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Belgium
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT05921929
- Official title
- Safety and Pharmacokinetics of a Novel NMDA Receptor Antagonist Against Brain Related Diseases in Healthy Adult Volunteers: First-in-human, Phase I, Single Dose-escalating, Open Label Study
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT05921929. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular follow-up, often through questionnaires or interviews.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
Based on the public registry summary, this study is trying to understand: The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: * What is the safety of single ascending doses of the FluoroEthylNorMemantine (FENM)? * What is the PK profile. The study team can confirm the exact objective and what it means for you.
Does this study involve a medication?
This appears to be a medication / drug study involving Fluoroethylnormemantine (FENM). The listed phase is PHASE1. Ask the study team what that means in practice for safety, monitoring, and criteria.
Who might this study be for?
This study may concern people with depression; age range: From 18 Years to 45 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by ReST Therapeutics, which appears to be a biotech company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is not currently recruiting. Check the official registry for the reason and latest status.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
RecruitingNCT05644301
INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder
This study is recruiting. It focuses on depression and currently lists participation information in Belgium.
RecruitingNCT06378229
Psilocybin for Hospitalized people with Treatment-resistant Depression
This study is recruiting. It focuses on depression and currently lists participation information in Belgium.
RecruitingNCT03320304
Effectiveness of Effectiveness and Efficiency of VNS Therapy in depression
This study is recruiting in the United Kingdom, in Belgium, in Austria, .... It is testing Effectiveness and Efficiency of VNS Therapy for depression.